Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original 2011 UCSF CAPRA-S

A six-factor postoperative prostate-cancer prognostic score after radical prostatectomy.

Evidence-based context for fast calculator use

Purpose:
Reproduce the original CAPRA-S total, risk group, and matched historical five-year progression-free outcome row.
Population:
Patients after radical prostatectomy with preoperative PSA and complete surgical pathology, resembling the original untreated cohort.
Factors:
Preoperative PSA, Pathologic Gleason, Surgical margins, Extracapsular extension, Seminal-vesicle invasion, Lymph-node involvement
Reference:
Cooperberg et al. Cancer. 2011;117(22):5039-5046. doi:10.1002/cncr.26169.
HomeCAPRA-S Score (Post-Surgical)
Pin your most used calculators here by clicking the star in the dropdown.

CAPRA-S Score (Post-Surgical)

ng/mL

Clinical Context & Background

This calculator reproduces the original 2011 UCSF Cancer of the Prostate Risk Assessment Postsurgical score (CAPRA-S). It assigns points for preoperative PSA, pathologic Gleason score, positive surgical margins, extracapsular extension, seminal-vesicle invasion, and lymph-node involvement. PSA is compared at full precision without rounding.
Scores 0-2, 3-5, and 6-12 are low, intermediate, and high risk. The score-specific 5-year progression-free probabilities shown are historical observations from the original radical-prostatectomy cohort, not individualized predictions.
Use after radical prostatectomy when preoperative PSA and complete surgical pathology are available. The original cohort excluded patients who received neoadjuvant or adjuvant treatment and those with clinically advanced disease before surgery. CAPRA-S does not estimate adjuvant-treatment benefit or recommend treatment.
Primary Source EvidenceCooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039-5046. doi:10.1002/cncr.26169.
Formula Logic
Original 2011 UCSF CAPRA-S: PSA <=6=0, >6-10=1, >10-20=2, >20=3; pathologic Gleason 2-6=0, 3+4=1, 4+3=2, 8-10=3; positive margin=2; extracapsular extension=1; seminal-vesicle invasion=2; lymph-node involvement=1. Total 0-12; low 0-2, intermediate 3-5, high >=6.

Reference Data

CAPRA-S ScoreRisk GroupHistorical 5-Year Progression-Free Probability
0Low94.5%
1Low91.0%
2Low83.3%
3Intermediate72.8%
4Intermediate70.2%
5Intermediate42.5%
6High25.9%
7High26.9%
8High12.3%
>=9High0%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use after radical prostatectomy when preoperative PSA and complete surgical pathology are available.
  • Enter raw, unrounded preoperative PSA and the final pathologic findings.

How To Interpret

  • Add all six source-defined contributions.
  • Scores 0-2 are low, 3-5 intermediate, and 6-12 high risk.
  • The score-specific five-year probabilities are historical cohort observations, not individualized predictions.

What To Do Next

  • Interpret with current pathology, postoperative PSA, comorbidity, contemporary guidelines, and specialist judgment.

Limitations

  • The original cohort excluded neoadjuvant/adjuvant treatment and clinically advanced preoperative disease.
  • Not a measure of adjuvant-treatment benefit or a treatment recommendation.
  • Not the preoperative CAPRA, CAPRA-S nomogram extension, or a genomic classifier.

Validated Population

Original radical-prostatectomy cohort with preoperative PSA and complete postoperative pathology, without neoadjuvant or adjuvant treatment.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls at CAPRA-S scores 0, 3, and 12.
    • Low, Intermediate, and High groups rendered as expected.
    • No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/capra-s-prostate-cancer-post-surgical-risk-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during the route load.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/capra-s-prostate-cancer-post-surgical-risk.json.

  3. : Browser input adapter corrected and reverified

    • Accepted finite number values already normalized by the shared calculator form while retaining strict malformed-input rejection.
    • No equation, cutoff, unit, classification, or applicability rule changed; calculator-specific verification and the calculator-wide browser-input audit passed.

  4. : Full validation test

    • 512/512 exhaustive model, raw PSA boundary, score-group, strict-input, UI, trace, historical-outcome, wording, immutability, registry, and no-panel checks passed with zero score or classification mismatches.
    • Scope is the original 2011 postoperative UCSF CAPRA-S after radical prostatectomy; no panel calculates CAPRA-S or inherits this status.

  5. : Calculation and input-contract correction

    • Replaced favorable pre-scored defaults and arbitrary summation with raw preoperative PSA plus exact semantic pathology categories and source-defined points.
    • Added strict exact-key, finite-value, enum, missing/extra-field, coercion, nonfinite, and immutability safeguards while preserving the permanent route and existing lvi input ID.
    • Restored exact score-specific 5-year progression-free probabilities for scores 0-8 and >=9, a six-factor trace, matched source row, and wording that does not imply individualized prognosis or adjuvant-treatment benefit.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

D'Amico Risk ClassificationJohns Hopkins Epstein T1c Pretreatment Criteria (1994 derivation; 1997 operational thresholds)PI-RADS® v2.1 Assessment Category Interpreter

Frequently Asked Questions

When should CAPRA-S Score (Post-Surgical) be used?

Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.

Can CAPRA-S Score (Post-Surgical) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.